Navigation Links
QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
Date:10/21/2013

Press-Releases/PressReleaseView/?PressReleaseID=418&lang=EN">EGFR mutations, including the most prevalent resistance mutation, T790M. The test supports efficient laboratory workflow with real-time PCR technology on the FDA approved Rotor-Gene Q MDx, which is part of the QIAsymphony family of laboratory solutions.

The development plan for the companion diagnostic complements Clovis Oncology's accelerated plan for CO-1686 development by potentially allowing a supplemental premarket approval (PMA) filing for the diagnostic. Subject to regulatory approvals, QIAGEN will be responsible for the global development and commercialization of the companion diagnostic, and Clovis will be responsible for the global development and commercialization of CO-1686. The partners also created the framework for possible future collaborations, thereby adding another master agreement to QIAGEN's growing pipeline of collaborations with some of the world's leading pharmaceutical and biotechnology companies. Further terms of the agreement were not disclosed.

"We are pleased to partner with Clovis Oncology in developing a companion diagnostic based on QIAGEN's therascreen technology and to expand the label of our approved therascreen EGFR kit. Together, we can accelerate the development of this important drug candidate and deliver a solution to an unmet medical need," said Peer Schatz, QIAGEN's Chief Executive Officer. "Our therascreen EGFR kit, approved by the FDA based on extensive analytical and clinical data, is the most comprehensive test and offers unique features such as detection of actionable mutations in separate tubes. QIAGEN is a preferred partner in personalized medicine because of our ability to deliver reproducible results, the efficient workflow of our platforms, and our track record in development and regulatory approvals."

"We are pleased to collaborate with QIAGEN for the development of a companio
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
2. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
5. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
6. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
7. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
8. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
9. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... IL (PRWEB) May 30, 2015 ... cutting-edge, novel research for bile duct cancer, announced ... launched Research Fellowship Program. , The ... outstanding scientists throughout the country to raise awareness ... funding will support research that opens new pathways ...
(Date:5/30/2015)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... BAX ) today announced data from PERSIST-1 – a ... treatment of myelofibrosis – in a late-breaking oral session ... Society of Clinical Oncology (ASCO), May 29-June 2, 2015 ... an investigational oral multikinase inhibitor with specificity for JAK2 ...
(Date:5/30/2015)... RARITAN, N.J. , May 30, ... two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show ... anti-CD38 monoclonal antibody – achieved an overall response ... as assessed by an independent review committee, in ... was consistent among the pre-specified subgroups based on ...
(Date:5/30/2015)... 2015  Caris Life Sciences® today announced the ... researchers identified biomarker changes, including key driver mutations, ... changes in response to therapy as the disease ... subset of a larger study analyzing 1,245 glioma ... These data utilizing Caris Molecular Intelligence®, the company,s ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... dream of competing together to race the fastest cars they ... group of 20 engineers, scientists and technicians from Ohio State ... is to win the $1 million dollar grand prize awarded ... , ,The Defense Advanced Research Projects Agency (DARPA) has ...
... Wis. -- Fiserv Inc., a provider ... Management, a portfolio management and investment accounting solution. ... trade execution, accounting, international settlement support and regulatory ... handle several accounting bases and closing dates and ...
... and community development specialist, presented a hopeful outlook for ... on Economic Development . Abstaining from morbid statistics and ... businesses in Wisconsin. , ,Wisconsin manufacturing suffered very little ... He cited that Wisconsin saw only a 9.1 percent ...
Cached Biology Technology:Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 2Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 3Optimistic Outlook For Manufacturing 2
(Date:5/29/2015)... , May 28, 2015 Research ... addition of the "Facial Recognition Market by ... - Global Forecast to 2020" report to ... have seen facial recognition technology become more efficient ... to gain traction and investment from the commercial ...
(Date:5/28/2015)... GLEN ALLEN, Va. , May 28, 2015 ... announced the release of a new report titled ... self-healing materials (reversible polymers, inorganic capsule and vascular ... self-healing coatings) will grow to around $2.7 billion ... latest deliverable from n-tech,s extensive coverage of smart ...
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... are small, lungless amphibians that live in moist, forest ... serve as vital links in forest food chains; their ... predict the health of forest ecosystems. Now, researchers at ... size reflects forest habitat quality and can predict how ...
... intracellular particle tracking (simultaneous tracking of the motions ... and even individual molecules), that is an important ... search for appropriate medicines against certain diseases (including ... winner. Techniques proposed by all the participants, ...
... levels of air pollutants were nearly three times as likely ... of pollution exposure, report researchers at Columbia University Medical Center ... both increased dramatically in the past 30 years. The percentage ... in 1980 to 20% in 2008. Childhood asthma is up ...
Cached Biology News:Salamanders help predict health of forest ecosystems and inform forest management 29 and 60 ways of particle tracking 29 and 60 ways of particle tracking 3Obese children more susceptible to asthma from air pollution 2
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... tubes are used to store 2.0 ml ... uniform walls for uniform heat transfer and ... caps. The O-rings are made of polyethylene ... from -55 to 150 degrees C. Supplied ...
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
Biology Products: